L-dopa in Parkinson’s disease
L-dopa at present is the most potent drug in the treatment of Parkinson’s disease (PD). The initiation of L-dopa has brought about an improvement in the quality of life and an increase in life expectancy. After long-term administration a declined efficacy, fluctuations in mobility and dyskinesias are to be seen.
It was supposed that L-dopa by producing toxic radicals may be the cause not only for the long-term treatment failure but also for the progression of the disease. Arguments in favor or against an early use of L-dopa are presented.
KeywordsParkinsonian Patient Dopaminergic Lesion Restricted Protein Intake Ingest Amino Acid Brain Dopamine Metabolism
Unable to display preview. Download preview PDF.
- Guillard A, Chastang C, Fenelon G (1986) Etude à long terme de 416 cas de maladie de parkinson. Facteurs de pronostic et implications thérapeutiques. Rev Neurol (Paris) 142: 207–214Google Scholar
- Hoehn MM (1983) Parkinsonism treated with levodopa, progression and mortality. J Neural Transm [Suppl] 19: 253–264Google Scholar
- Sage JI, Trooskin S, Heikkila R (1987) Long-term duodenal infusion of levo-dopa for on-off phenomena in parkinsonism: Continued good clinical response associated with gradually declining levodopa in take. Ann Neurol 22: 173Google Scholar
- Stern G (1987) Prognosis in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 91–98Google Scholar